View More Recent Stories

Sep 10, 2024 07:02AM Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
Aug 30, 2024 07:35AM Needham Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Aug 14, 2024 03:58PM Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jul 25, 2024 02:29PM Viridian Therapeutics (VRDN) September 15 puts active as share price trades $16.53
Jul 16, 2024 10:52AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jul 15, 2024 01:23PM BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 12:52PM Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 12:47PM RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 12:32PM BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 05:02AM Wolfe Research Starts Viridian Therapeutic (VRDN) at Outperform
View More Recent Stories